[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554258":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":46,"responsibleParty":124,"collaborators":44,"id":127,"slug":44,"hasResults":128,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":128,"sex":134,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":44,"studyType":140,"phases":141,"briefSummary":143,"conditions":144,"keywords":44,"overallStatus":49,"whyStopped":44,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Ketamine","EXPERIMENTAL","Participants will receive IV ketamine (0.50mg\u002Fkg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks.",[13],"Drug: Ketamine Hydrochloride",{"label":15,"type":16,"description":17,"interventionNames":18},"Midazolam","ACTIVE_COMPARATOR","Participants will receive IV midazolam (0.02mg\u002Fkg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks.",[19],"Drug: Midazolam Hydrochloride",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ketamine Hydrochloride","Participants will receive IV ketamine (0.50mg\u002Fkg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.",[9],[27],"Ketelar",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Midazolam Hydrochloride","Participants will receive IV midazolam (0.02mg\u002Fkg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump over 45 minutes. Duration of each infusion may be extended by the Study Clinician supervising study medication infusion if slower infusion rate is better tolerated.",[15],[33],"Versed",[35],{"name":36,"affiliation":37,"role":38},"Madhukar Trivedi, MD","Professor (Tenured)","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Angela Casey-Willingham","CONTACT","214-648-4689",null,"Angela.Casey-Willingham@UTSouthwestern.edu",[47,71,82,92,113],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Alameda Health System","RECRUITING","San Leandro","California","94578","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-122.15608,37.72493,{"lat":59,"lon":58},[62,66,69],{"name":63,"role":42,"phone":64,"phoneExt":44,"email":65},"Stephanie Gallardo, BA","510-495-4643","stgallardo@alamedahealthsystem.org",{"name":67,"role":42,"phone":68,"phoneExt":44,"email":44},"Bridge Clinic","510-545-2765",{"name":70,"role":38,"phone":44,"phoneExt":44,"email":44},"Erik Anderson, MD",{"facility":72,"status":73,"city":74,"state":75,"zip":76,"country":53,"countryCode":54,"cosmosGeoPoint":77,"geoPoint":81,"contacts":44},"Interdisciplinary Substance Use and Brain Injury Facility","COMPLETED","Albuquerque","New Mexico","87106",{"type":56,"coordinates":78},[79,80],-106.65114,35.08449,{"lat":80,"lon":79},{"facility":83,"status":84,"city":85,"state":85,"zip":86,"country":53,"countryCode":54,"cosmosGeoPoint":87,"geoPoint":91,"contacts":44},"Addiction Institute of Mount Sinai","TERMINATED","New York","10029",{"type":56,"coordinates":88},[89,90],-74.00597,40.71427,{"lat":90,"lon":89},{"facility":93,"status":49,"city":94,"state":95,"zip":96,"country":53,"countryCode":54,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Prisma Health","Greenville","South Carolina","29617",{"type":56,"coordinates":98},[99,100],-82.39401,34.85262,{"lat":100,"lon":99},[103,107,111],{"name":104,"role":42,"phone":105,"phoneExt":44,"email":106},"Sarah","864-960-3183","sarah.feingold@prismahealth.org",{"name":108,"role":42,"phone":109,"phoneExt":44,"email":110},"Anthony","864-735-8682","Anthony.Faso@prismahealth.org",{"name":112,"role":38,"phone":44,"phoneExt":44,"email":44},"Alain Litwin, MD",{"facility":114,"status":115,"city":116,"state":117,"zip":118,"country":53,"countryCode":54,"cosmosGeoPoint":119,"geoPoint":123,"contacts":44},"UT Southwestern Medical Center","ACTIVE_NOT_RECRUITING","Dallas","Texas","75247",{"type":56,"coordinates":120},[121,122],-96.80667,32.78306,{"lat":122,"lon":121},{"type":38,"investigatorFullName":125,"investigatorTitle":126,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Madhukar H. Trivedi, MD","Professor-Psychiatry","100554258",false,"NCT06496750","Ketamine for Methamphetamine Use Disorder","NIDA CTN-0132 Randomized, Double-Blind, Active Placebo-Controlled Trial of Ketamine for Methamphetamine Use Disorder (KMD)","KMD","Inclusion criteria\n\nStudy participants must:\n\n1. Be 18 to 65 years old\n2. Be able to sufficiently understand, speak, and read English\n3. Be interested in reducing or stopping methamphetamine use\n4. Meet criteria for methamphetamine use disorder\n5. Use acceptable methods of contraception during participation in the study\n\nExclusion criteria\n\nStudy participants must not:\n\n1. Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent\n2. Be currently in jail, prison, or inpatient overnight facility as required by court of law\n3. Have upcoming surgery planned or scheduled\n4. Be currently pregnant, breastfeeding, or planning on conception, if biologically female\n\nAdditional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit.","ALL","18 Years","65 Years",{"count":138,"type":139},120,"ESTIMATED","INTERVENTIONAL",[142],"PHASE2","This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.\n\nThe study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).",[145,146,147],"Substance Use Disorders","Substance Use","Methamphetamine Abuse","2026-03-30",{"date":150,"type":151},"2026-04-01","ACTUAL",{"date":153,"type":151},"2024-09-11",{"date":155,"type":139},"2026-10-15",{"name":5,"class":6},5]